Biocon collaborates with JDRF

JDRF provides financial support to accelerate breakthrough research in Type 1 Diabetes management

Biocon and JDRF, a leading global organisation funding type 1 diabetes (T1D) research and advocacy worldwide, jointly announced a JDRF partnership to support a global multiple ascending dose study with a novel oral insulin drug candidate, Insulin Tregopil, in people with T1D.

Insulin Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programmes in the global oral insulin space. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management.

Biocon proposes to conduct an open label study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of multiple ascending doses of Insulin Tregopil and to compare the PK, PD and safety of the optimal dose regimen of Insulin Tregopil with therapeutic doses of Insulin Aspart in individuals with T1D.

This collaboration with Biocon is a part of JDRF’s Industry Discovery and Development Partnership (IDDP) programme, through which JDRF provides financial support to accelerate breakthrough research in T1D management.

Commenting on the collaboration, Kiran Mazumdar-Shaw, CMD, Biocon said, "We believe Insulin Tregopil can make a significant difference to the diabetes management paradigm for both type I and type II diabetes and welcome JDRF’s support in advancing this unique oral insulin molecule through the clinic for type II diabetes. With this proposed clinical study, we hope to build on the extremely promising data that we have generated so far through previous human trials with Tregopil. We are committed to addressing the huge unmet need of people with diabetes by providing the medical community an alternate treatment for postprandial hyperglycaemia."

"JDRF has been supportive of oral insulin studies to help people with type I diabetes better manage their glucose levels with less need for injected insulin," said Esther Latres, JDRF Director, Translational Development, "To achieve that goal would be one incredible step toward improving the quality of life for people with T1D while we strive for our ultimate goal of a cure."

Dr Narendra Chirmule, Sr VP & Head of R&D, Biocon, added, "We are thankful to JDRF for extending their support to our R&D efforts that are aimed at developing a novel oral insulin to treat type I diabetes. The primary objective of this study will be to evaluate the safety and tolerability of multiple ascending doses of Insulin Tregopil in individuals with type I diabetes. We are excited to work on this novel molecule and to partner with the world’s leading organisation supporting T1D research, JDRF."